
News|Slideshows|August 11, 2021
8 Questions on Diabetes Drugs for Cardioprotection
Author(s)Leo Robert
Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.
Advertisement
Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.
Take this quick quiz to test your knowledge of key findings.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Survey Finds Most PCPs Do Not Use uACR to Assess Cardiovascular Risk in Type 2 Diabetes
2
COVID-19 Vaccination Linked to Lower Risk of Severe Outcomes in Pregnancy Across Delta and Omicron Periods
3
FDA Accepts Supplemental Application for Teplizumab to Delay Stage 3 Type 1 Diabetes in Children Aged 1 Year and Older
4
Digital Screening Tool Duo Shows Promise for ADRD Detection in Primary Care: Daily Dose
5


























































































































































































































































































































